Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shampa Das

Showing results (21-30 of 51) with videos related to

Pageof 6
Sort By:
Critical Care (London, England)|February 21, 2012
A placebo-controlled, double-blind, dose-escalation study to assess the safety, tolerability and pharmacokinetics/pharmacodynamics of single and multiple intravenous infusions of AZD9773 in patients with severe sepsis and septic shockPeter E Morris, Brian Zeno, Andrew C Bernard, et al.
Antimicrobial Agents and Chemotherapy|August 27, 2024
<i>Acinetobacter baumannii</i> transformants expressing oxacillinases and metallo-β-lactamases that confer resistance to meropenem: new tools for anti-<i>Acinetobacter</i> drug development and AMR preparednessVineet Dubey, Nicola Farrington, Nicholas Harper, et al.
Paediatric Drugs|August 26, 2021
Potential Antibiotics for the Treatment of Neonatal Sepsis Caused by Multidrug-Resistant BacteriaChristopher A Darlow, Renata M A da Costa, Sally Ellis, et al.
Antimicrobial Agents and Chemotherapy|January 24, 2019
Dose Selection and Validation for Ceftazidime-Avibactam in Adults with Complicated Intra-abdominal Infections, Complicated Urinary Tract Infections, and Nosocomial PneumoniaShampa Das, Jianguo Li, Todd Riccobene, et al.
International Journal of Antimicrobial Agents|February 5, 2019
Ceftaroline fosamil therapy in patients with acute bacterial skin and skin-structure infections with systemic inflammatory signs: A retrospective dose comparison across three pivotal trialsG Ralph Corey, Mark H Wilcox, Jesus Gonzalez, et al.
Journal of Family Medicine and Primary Care|August 15, 2025
Seroprevalence of scrub typhus among patients with acute febrile illness: A study from northern districts of West BengalSantanu Hazra, Arpita P Dutta, Sumana Moitra, et al.
European Journal of Clinical Pharmacology|January 22, 2024
Dose selection for aztreonam-avibactam, including adjustments for renal impairment, for Phase IIa and Phase III evaluationShampa Das, Todd Riccobene, Timothy J Carrothers, et al.
Investigational New Drugs|June 5, 2012
Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumorsGary K Schwartz, Richard D Carvajal, Rachel Midgley, et al.
Antimicrobial Agents and Chemotherapy|August 1, 2018
Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosaWright W Nichols, Gregory G Stone, Paul Newell, et al.
Antimicrobial Agents and Chemotherapy|March 22, 2022
Pharmacodynamics of Meropenem and Tobramycin for Neonatal Meningoencephalitis: Novel Approaches to Facilitate the Development of New Agents to Address the Challenge of Antimicrobial ResistanceNicola Farrington, Laura McEntee, Adam Johnson, et al.
Pageof 6

Showing results (21-30 of 51) with videos related to

Sort By:
Pageof 6
Critical Care (London, England)|February 21, 2012
A placebo-controlled, double-blind, dose-escalation study to assess the safety, tolerability and pharmacokinetics/pharmacodynamics of single and multiple intravenous infusions of AZD9773 in patients with severe sepsis and septic shockPeter E Morris, Brian Zeno, Andrew C Bernard, et al.
Antimicrobial Agents and Chemotherapy|August 27, 2024
<i>Acinetobacter baumannii</i> transformants expressing oxacillinases and metallo-β-lactamases that confer resistance to meropenem: new tools for anti-<i>Acinetobacter</i> drug development and AMR preparednessVineet Dubey, Nicola Farrington, Nicholas Harper, et al.
Paediatric Drugs|August 26, 2021
Potential Antibiotics for the Treatment of Neonatal Sepsis Caused by Multidrug-Resistant BacteriaChristopher A Darlow, Renata M A da Costa, Sally Ellis, et al.
Antimicrobial Agents and Chemotherapy|January 24, 2019
Dose Selection and Validation for Ceftazidime-Avibactam in Adults with Complicated Intra-abdominal Infections, Complicated Urinary Tract Infections, and Nosocomial PneumoniaShampa Das, Jianguo Li, Todd Riccobene, et al.
International Journal of Antimicrobial Agents|February 5, 2019
Ceftaroline fosamil therapy in patients with acute bacterial skin and skin-structure infections with systemic inflammatory signs: A retrospective dose comparison across three pivotal trialsG Ralph Corey, Mark H Wilcox, Jesus Gonzalez, et al.
Journal of Family Medicine and Primary Care|August 15, 2025
Seroprevalence of scrub typhus among patients with acute febrile illness: A study from northern districts of West BengalSantanu Hazra, Arpita P Dutta, Sumana Moitra, et al.
European Journal of Clinical Pharmacology|January 22, 2024
Dose selection for aztreonam-avibactam, including adjustments for renal impairment, for Phase IIa and Phase III evaluationShampa Das, Todd Riccobene, Timothy J Carrothers, et al.
Investigational New Drugs|June 5, 2012
Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumorsGary K Schwartz, Richard D Carvajal, Rachel Midgley, et al.
Antimicrobial Agents and Chemotherapy|August 1, 2018
Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosaWright W Nichols, Gregory G Stone, Paul Newell, et al.
Antimicrobial Agents and Chemotherapy|March 22, 2022
Pharmacodynamics of Meropenem and Tobramycin for Neonatal Meningoencephalitis: Novel Approaches to Facilitate the Development of New Agents to Address the Challenge of Antimicrobial ResistanceNicola Farrington, Laura McEntee, Adam Johnson, et al.
Pageof 6